INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Portfolio Pulse from
Pomerantz LLP has filed a class action lawsuit against Intellia Therapeutics (NTLA) following the company's announcement of strategic changes. On January 9, 2025, Intellia disclosed plans to focus on specific drug candidates, discontinue NTLA-3001, cut 27% of its workforce, and see the retirement of its Chief Scientific Officer. The stock price dropped 15.14% to $10.20 on January 10, 2025, prompting the legal action.
April 01, 2025 | 4:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Potential securities fraud allegations emerge following company's strategic restructuring and workforce reduction
The class action lawsuit, combined with significant strategic changes and workforce reduction, suggests potential negative investor sentiment and legal risk for Intellia Therapeutics
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100